Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti‐PD‐1 therapy

Renal‐cell carcinoma (RCC) is responsible for the majority of tumors arising from the kidney parenchyma. Although a progressive improvement in median overall survival has been observed after the introduction of anti‐PD‐1 therapy, many patients do not benefit from this treatment. Therefore, we have i...

Descripción completa

Detalles Bibliográficos
Autores principales: De Biasi, Sara, Guida, Annalisa, Lo Tartaro, Domenico, Fanelli, Martina, Depenni, Roberta, Dominici, Massimo, Finak, Greg, Porta, Camillo, Paolini, Annamaria, Borella, Rebecca, Bertoldi, Carlo, Cossarizza, Andrea, Sabbatini, Roberto, Gibellini, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542732/
https://www.ncbi.nlm.nih.gov/pubmed/35507402
http://dx.doi.org/10.1002/cyto.a.24562
Descripción
Sumario:Renal‐cell carcinoma (RCC) is responsible for the majority of tumors arising from the kidney parenchyma. Although a progressive improvement in median overall survival has been observed after the introduction of anti‐PD‐1 therapy, many patients do not benefit from this treatment. Therefore, we have investigated T cell dynamics to find immune modification induced by anti‐PD‐1 therapy. Here, we show that, after therapy, RCC patients (5 responders and 14 nonresponders) are characterized by a redistribution of different subsets across the memory T cell compartment.

Ejemplares similares